NUFORMIX PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1941 GBX | -2.95% |
|
-5.32% | -40.28% |
| Mar. 01 | Nuformix announces subscription to raise GBP150,000 | AN |
| Jan. 15 | Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023 | CI |
| Sales 2022 | 50K 62.59K | Sales 2023 | - | Capitalization | 1.94M 2.42M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.25M | Net income 2023 | - 0 | EV / Sales 2022 | 41.8 x |
| Net cash position 2022 | 464K 581K | Net cash position 2023 | 203K 254K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.94
x | P/E ratio 2023 |
-3.27
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.95% | ||
| 1 week | -5.32% | ||
| Current month | +2.16% | ||
| 1 month | +2.16% | ||
| 3 months | -50.23% | ||
| 6 months | -30.68% | ||
| Current year | -40.28% |
1 week
0.18
0.22
1 month
0.180.23
Current year
0.180.44
1 year
0.180.44
3 years
0.182.70
5 years
0.1814.89
10 years
0.1814.89
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
FOU | Founder | 51 | 07-12-31 |
Ben Harber
SEC | Corporate Secretary | 47 | 20-12-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Gilbert
CHM | Chairman | 63 | 20-11-23 |
| Director/Board Member | 59 | 20-12-01 | |
Daniel Gooding
FOU | Founder | 51 | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.1941 | -2.95% | 48 258 |
| 24-04-25 | 0.2 | +8.11% | 1,383,071 |
| 24-04-24 | 0.185 | -9.76% | 2,426,055 |
| 24-04-23 | 0.205 | -1.20% | 1,347,616 |
| 24-04-22 | 0.2075 | +1.22% | 2,745,777 |
Delayed Quote London S.E., April 26, 2024 at 03:32 am EDT
More quotes
Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001 is pursuing licensing opportunities. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.28% | 2.05M | |
| +24.78% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.08% | 233B | |
| +5.53% | 201B | |
| -10.18% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- LVRT Stock
